Results of ACCURATE study show advantage of Axium Neurostimulator System in pain relief- St Jude Medical
St. Jude Medical has announced long term data from the ACCURATE study has confirmed dorsal root ganglion (DRG) stimulation with the St. Jude Medical Axium Neurostimulator System provides sustained and superior pain relief over traditional spinal cord stimulation (SCS) in patients with complex regional pain syndrome (CRPS) or peripheral causalgia. In addition, patients receiving DRG stimulation reported better therapeutic targeting and a reduction in paresthesia (the tingling feeling common to traditional SCS) compared to traditional tonic SCS.
Results show sustained and superior pain relief: after 12 months, the ACCURATE study demonstrated a statistically significantly number of patients receiving DRG stimulation achieved meaningful pain relief and greater treatment success when compared to patients receiving traditional SCS (74.2 percent vs. 53 percent). The study also shows improved therapeutic targeting: Nearly all patients receiving DRG stimulation reported better stimulation targeting in their area of pain without extraneous paresthesia than patients receiving traditional SCS (94.5 percent vs. 61.2 percent). Finally it shows reduced paresthesia: After 12 months, more than a third of patients who received DRG stimulation were experiencing greater than 80 percent pain relief with no paresthesia. St. Jude Medical submitted their premarket approval submission to the FDA for approval of DRG stimulation in Q1 2015.
Related news and insights
Eli Lilly and Company and Incyte announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Olumiant (baricitinib) for the treatment of adults with severe alopecia areata (AA).
Regeneron Pharmaceuticals, Inc. and Sanofi announced that the FDA has approved Dupixent (dupilumab) 300 mg weekly to treat patients with eosinophilic esophagitis (EoE) aged 12 years and older, weighing at least 40 kg.
Mirati Therapeutics announced that it has submitted a Marketing Authorization Application to the European Medicines Agency for MRTX 849 (adagrasib) for the treatment of patients with non-small cell lung cancer (NSCLC) harboring the KRASG12C mutation who have received at least one prior systemic therapy.